News
Read all about our latest news.
Stratified medicine company Monument Therapeutics announces the start of its first clinical study for MT1980, a novel treatment for neuroinflammation
Our CEO Jennifer Barnett is featured in The Guardian in an important article discussing the critical impact of postoperative cognitive dysfunction (POCD)
Contact Us
We believe that neuroscience will be in the next decade what oncology has been in the last.
